Skip to main content

Breast Cancer Research and Treatment

Ausgabe 3/2010

Inhalt (36 Artikel)

Preclinical study

Evaluation of the histological size of the sentinel lymph node metastases using RT–PCR assay: a rapid tool to estimate the risk of non-sentinel lymph node invasion in patients with breast cancer

I. Veys, S. Majjaj, R. Salgado, D. Noterman, J. C. Schobbens, F. Manouach, P. Bourgeois, J. M. Nogaret, D. Larsimont, V. Durbecq

Preclinical study

Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers

Isabella Castellano, Elena Allia, Valeria Accortanzo, Anna Maria Vandone, Luigi Chiusa, Riccardo Arisio, Antonio Durando, Michela Donadio, Gianni Bussolati, Alan S. Coates, Giuseppe Viale, Anna Sapino

Invited Commentary

The androgen receptor in breast cancer: learning from the past

Michaela J. Higgins, Antonio C. Wolff

Preclinical study

Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells

Demissew S. Mern, Karin Hoppe-Seyler, Felix Hoppe-Seyler, Jens Hasskarl, Barbara Burwinkel

Preclinical study

Increased MUTYH mutation frequency among Dutch families with breast cancer and colorectal cancer

Marijke Wasielewski, Astrid A. Out, Joyce Vermeulen, Maartje Nielsen, Ans van den Ouweland, Carli M. J. Tops, Juul T. Wijnen, Hans F. A. Vasen, Marjan M. Weiss, Jan G. M. Klijn, Peter Devilee, Frederik J. Hes, Mieke Schutte

Preclinical study

Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age

Dorina M. van der Kolk, Geertruida H. de Bock, Beike K. Leegte, Michael Schaapveld, Marian J. E. Mourits, Jakob de Vries, Annemieke H. van der Hout, Jan C. Oosterwijk

Preclinical study

Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study

Konstantin J. Dedes, Maria-Angeles Lopez-Garcia, Felipe C. Geyer, Maryou B. K. Lambros, Kay Savage, Radost Vatcheva, Paul Wilkerson, Daniel Wetterskog, Magali Lacroix-Triki, Rachael Natrajan, Jorge S. Reis-Filho

Preclinical study

The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS)

N. Fortunati, M. G. Catalano, F. Marano, V. Mugoni, M. Pugliese, O. Bosco, F. Mainini, G. Boccuzzi

Preclinical study

Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma

Fangfang Liu, Lifang Cui, Yang Zhang, Ling Chen, Yahong Wang, Yu Fan, Ting Lei, Feng Gu, Ronggang Lang, Gordon A. Pringle, Xinmin Zhang, Zhinan Chen, Li Fu

Clinical trial

Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features

Emilia Montagna, Vincenzo Bagnardi, Nicole Rotmensz, Giuseppe Viale, Giancarlo Pruneri, Paolo Veronesi, Giuseppe Cancello, Alessandra Balduzzi, Silvia Dellapasqua, Anna Cardillo, Alberto Luini, Stefano Zurrida, Oreste Gentilini, Mauro Giuseppe Mastropasqua, Luca Bottiglieri, Monica Iorfida, Aron Goldhirsch, Marco Colleoni

Clinical trial

A practical approach to manage additional lesions at preoperative breast MRI in patients eligible for breast conserving therapy: results

Lotte E. Elshof, Emiel J. Th. Rutgers, Eline E. Deurloo, Claudette E. Loo, Jelle Wesseling, Kenneth E. Pengel, Kenneth G.A. Gilhuijs

Clinical trial

Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival

Sylvia Adams, A. Bapsi Chakravarthy, Martin Donach, Darcy Spicer, Stella Lymberis, Baljit Singh, Joshua A. Bauer, Tsivia Hochman, Judith D. Goldberg, Franco Muggia, Robert J. Schneider, Jennifer A. Pietenpol, Silvia C. Formenti

Clinical trial

Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance

Xinmin Zhao, Xiaofeng Xu, Lin Guo, Joseph Ragaz, Haiyi Guo, Jiong Wu, Zhimin Shao, Ji Zhu, Xiaomao Guo, Jiayi Chen, Beiling Zhu, Zhonghua Wang, Xichun Hu

Epidemiology

Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues

Vincent Launay-Vacher, Joseph Gligorov, Christophe Le Tourneau, Nicolas Janus, Jean-Philippe Spano, Isabelle Ray-Coquard, Stéphane Oudard, Xavier Pourrat, Jean-François Morere, Gilbert Deray, Philippe Beuzeboc

Epidemiology

BRCA1/2 test results impact risk management attitudes, intentions, and uptake

Suzanne C. O’Neill, Heiddis B. Valdimarsdottir, Tiffani A. DeMarco, Beth N. Peshkin, Kristi D. Graves, Karen Brown, Karen E. Hurley, Claudine Isaacs, Sharon Hecker, Marc D. Schwartz

Epidemiology

MTRR A66G polymorphism and breast cancer risk: a meta-analysis

Jia Hu, Guo-Wu Zhou, Ning Wang, Ya-Jie Wang

Epidemiology

Recording of hormone therapy and breast density in breast screening programs: summary and recommendations of the International Cancer Screening Network

Brian Cox, Rachel Ballard-Barbash, Mireille Broeders, Emily Dowling, Nea Malila, Rene Shumak, Stephen Taplin, Diana Buist, Diana Miglioretti

Epidemiology

Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients

E. Bastiaannet, G. J. Liefers, A. J. M. de Craen, P. J. K. Kuppen, W. van de Water, J. E. A. Portielje, L. G. M. van der Geest, M. L. G. Janssen-Heijnen, O. M. Dekkers, C. J. H. van de Velde, R. G. J. Westendorp

Epidemiology

Association between androgen receptor gene CAG repeat polymorphism and breast cancer risk: a meta-analysis

YouJin Hao, Rafael Montiel, BingHui Li, Enyi Huang, Lewie Zeng, YongSheng Huang

Epidemiology

Three polymorphisms in interleukin-1β gene and risk for breast cancer: a meta-analysis

Xiaoan Liu, Zhanwei Wang, Jinhua Yu, Gang Lei, Shui Wang

Epidemiology

Plasma tea polyphenol levels and subsequent risk of breast cancer among Japanese women: a nested case–control study

Motoki Iwasaki, Manami Inoue, Shizuka Sasazuki, Tsutomu Miura, Norie Sawada, Taiki Yamaji, Taichi Shimazu, Walter C. Willett, Shoichiro Tsugane

Epidemiology

A longitudinal study of factors associated with perceived risk of recurrence in women with ductal carcinoma in situ and early-stage invasive breast cancer

Ying Liu, Maria Pérez, Mario Schootman, Rebecca L. Aft, William E. Gillanders, Matthew J. Ellis, Donna B. Jeffe

Brief Report

Breast-conserving therapy after previous irradiation for lymphoma

Sonia K. A. Nguyen, Anne Dagnault

Brief Report

Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer

Yonglan Zheng, Jing Zhang, Kisha Hope, Qun Niu, Dezheng Huo, Olufunmilayo I. Olopade

Brief Report

Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer

Diana S. M. Buist, Linn A. Abraham, William E. Barlow, Arun Krishnaraj, Regan C. Holdridge, Edward A. Sickles, Patricia A. Carney, Karla Kerlikowske, Berta M. Geller

Brief Report

Maternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case report

Brunella Pilato, Simona De Summa, Katia Danza, Rossana Lambo, Angelo Paradiso, Stefania Tommasi

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.